Skip to content

Study · Animal study (in vivo) · rat · 1986

11 results

Effects of dipyridamole and furosemide on renal function during adenine dinucleotide infusion in rats.

Redlak M, Szczepańska-Konkel M, Stepiński J, Angielski S

Acta physiologica Polonica1 Jan 1986Cited by 1 (Europe PMC)

PMID3788606 (opens in a new tab)PepBankPUB-03788606
Publisher pageAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In anaesthetized rats, NAD infusion decreased renal plasma flow.

    In plain wordsIn rats, NAD infusion decreased blood plasma flow through the kidneys.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseRenal plasma flow
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    200 nmole X kg-1 X X min-1 · intravenousAs given in this study (rat).

    Source sentences

    Summary
    In anaesthetized rats kept on normal diet an i.v. infusion of NAD (200 nmole X kg-1 X X min-1) induced a decrease in renal plasma flow (CPAH), glomerular filtration rate (GFR) and electrolyte excretion accompanied by an increase in plasma adenosine concentration.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In anaesthetized rats, NAD infusion decreased glomerular filtration rate.

    In plain wordsIn rats, NAD infusion decreased kidney filtration.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseGlomerular filtration rate
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    200 nmole X kg-1 X X min-1 · intravenousAs given in this study (rat).

    Source sentences

    Summary
    In anaesthetized rats kept on normal diet an i.v. infusion of NAD (200 nmole X kg-1 X X min-1) induced a decrease in renal plasma flow (CPAH), glomerular filtration rate (GFR) and electrolyte excretion accompanied by an increase in plasma adenosine concentration.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In anaesthetized rats, NAD infusion decreased electrolyte excretion.

    In plain wordsIn rats, NAD infusion decreased electrolyte excretion.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseElectrolyte excretion
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    200 nmole X kg-1 X X min-1 · intravenousAs given in this study (rat).

    Source sentences

    Summary
    In anaesthetized rats kept on normal diet an i.v. infusion of NAD (200 nmole X kg-1 X X min-1) induced a decrease in renal plasma flow (CPAH), glomerular filtration rate (GFR) and electrolyte excretion accompanied by an increase in plasma adenosine concentration.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In anaesthetized rats, NAD infusion increased plasma adenosine concentration.

    In plain wordsIn rats, NAD infusion increased blood adenosine levels.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreasePlasma adenosine concentration
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    200 nmole X kg-1 X X min-1 · intravenousAs given in this study (rat).

    Source sentences

    Summary
    In anaesthetized rats kept on normal diet an i.v. infusion of NAD (200 nmole X kg-1 X X min-1) induced a decrease in renal plasma flow (CPAH), glomerular filtration rate (GFR) and electrolyte excretion accompanied by an increase in plasma adenosine concentration.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In anaesthetized rats, low-dose NAD infusion did not affect renal function.

    In plain wordsIn rats, low-dose NAD infusion did not change kidney function.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    No significant changeRenal function at low NAD dose
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    50 nmole X kg-1 X min-1 · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Separate infusions of a small dose of NAD (50 nmole X kg-1 X min-1) or dipyridamole (25 micrograms X kg-1 X min-1) did not affect renal function or plasma adenosine concentration.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In anaesthetized rats, low-dose NAD infusion did not affect plasma adenosine concentration.

    In plain wordsIn rats, low-dose NAD infusion did not change blood adenosine levels.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    No significant changePlasma adenosine at low NAD dose
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    50 nmole X kg-1 X min-1 · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Separate infusions of a small dose of NAD (50 nmole X kg-1 X min-1) or dipyridamole (25 micrograms X kg-1 X min-1) did not affect renal function or plasma adenosine concentration.

Studies that did not test the peptide alone5

In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  1. 07AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In anaesthetized rats, simultaneous low-dose NAD and dipyridamole significantly decreased glomerular filtration rate.

    In plain wordsIn rats, combined low-dose NAD and dipyridamole decreased kidney filtration.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseGlomerular filtration with dipyridamole
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    However, when the above small doses of both agents were given simultaneously, GFR, CPAH and electrolyte excretion fell significantly, indicating potentiation of NAD action by dipyridamole, associated with increased plasma adenosine level.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  2. 08AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In anaesthetized rats, simultaneous low-dose NAD and dipyridamole significantly decreased renal plasma flow.

    In plain wordsIn rats, combined low-dose NAD and dipyridamole decreased kidney blood plasma flow.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseRenal plasma flow with dipyridamole
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    However, when the above small doses of both agents were given simultaneously, GFR, CPAH and electrolyte excretion fell significantly, indicating potentiation of NAD action by dipyridamole, associated with increased plasma adenosine level.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  3. 09AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In anaesthetized rats, simultaneous low-dose NAD and dipyridamole significantly decreased electrolyte excretion.

    In plain wordsIn rats, combined low-dose NAD and dipyridamole decreased electrolyte excretion.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseElectrolyte excretion with dipyridamole
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    However, when the above small doses of both agents were given simultaneously, GFR, CPAH and electrolyte excretion fell significantly, indicating potentiation of NAD action by dipyridamole, associated with increased plasma adenosine level.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  4. 10AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In anaesthetized rats, simultaneous low-dose NAD and dipyridamole increased plasma adenosine levels.

    In plain wordsIn rats, combined low-dose NAD and dipyridamole increased blood adenosine levels.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreasePlasma adenosine with dipyridamole
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    However, when the above small doses of both agents were given simultaneously, GFR, CPAH and electrolyte excretion fell significantly, indicating potentiation of NAD action by dipyridamole, associated with increased plasma adenosine level.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  5. 11AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In anaesthetized rats, furosemide infusion failed to abolish NAD-induced depression of renal function.

    In plain wordsIn rats, furosemide did not prevent kidney function depression during NAD exposure.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    No significant changeFurosemide effect on NAD-induced renal depression
    Study

    ratn: not reported in source

    anaesthetized rats on normal diet
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    An i.v. infusion of furosemide failed to abolish the depression of renal function in response to NAD.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.